The rotation into value, financials, and industrials is accelerating faster than most investors realize.
Year: 2026
Big Pharma Has $1.3 Trillion to Spend. The Clock Is Running.
A patent cliff with a known deadline is forcing the largest acquisition wave in biopharma history.
Tesla Delivered 480,126 Cars. The Stock Dropped 7% Anyway.
The delivery beat was never really the question. July 22 is.
Bending Spoons Is Now Public. The Story Has 1,000 Chapters Left.
An Italian software roll-up just had one of the year's best IPO debuts.
Vertiv Is Up 73% in 2026. Now Comes the Hard Part.
Q2 earnings are *estimated* for July 29. The backlog is massive. The valuation is not cheap.
Meta Just Became Its Own Competition
A $125 billion AI infrastructure budget is about to flip from cost center to revenue engine.
NVDA Is Down 17% From Its High. The August 26 Earnings Date Is the Only Number That Matters.
Record revenue, a $91B guide, and a stock that won't hold gains. Here is where the trade actually lives.
Three Jobs Reports in Three Days. The Market Has No Escape Hatch.
JOLTS, ADP, and NFP are stacked back-to-back this week. What happens Thursday stays locked in through a four-day weekend.
Rocket Lab Just Changed the Space Economy Overnight
An $8 billion Iridium deal turns RKLB into a vertically integrated satellite powerhouse.
Nike Reports Tomorrow. The Number Everyone Will Ignore Is the One That Matters.
With Q4 earnings due Tuesday, the real debate isn't the revenue miss — it's whether gross margin can hold.